Brendan Byrne

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

Thomas Louie, Kristine Cannon, Brendan Byrne et al. · Clinical Infectious Diseases · 2012 · 305 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

Gerald W. Tannock, Karen Munro, Corinda Taylor et al. · Microbiology · 2010 · 215 citations

Life Sciences, Infectious Diseases, Microbiology +15

OPT-80 Eliminates <i>Clostridium difficile</i> and Is Sparing of <i>Bacteroides</i> Species during Treatment of <i>C. difficile</i> Infection

Thomas Louie, Judy Emery, Walter Krulicki et al. · Antimicrobial Agents and Chemotherapy · 2008 · 190 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

General characteristics of protein degradation in diabetes and starvation.

J. Fred Dice, Carlos D. Walker, Brendan Byrne et al. · Proceedings of the National Academy of Sciences · 1978 · 127 citations · Full text

Life Sciences, Biochemistry, Physiology +16

An altered hormonal profile and elevated rate of bone loss are associated with low bone mass in professional horse-racing jockeys

Eimear Dolan, Adrian McGoldrick, Colin Davenport et al. · Journal of Bone and Mineral Metabolism · 2012 · 72 citations

Medicine, Endocrinology, Sports Medicine +17